文献速递前列腺癌

前列腺癌磁共振可见病灶靶向活检的过度分级是否导致过度治疗

Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
PubMed 文献 · Eur Urol · 2024-03-16

回顾性分析8家转诊中心1020例活检初治、MRI靶向活检GG≥2且PI-RADS≥3的前列腺癌患者,以根治性前列腺切除标本为参照,评估靶向活检过度分级导致的过度治疗风险。结果显示靶向活检总体过度治疗风险为2.7%(28/1020),经会阴活检路径与降级风险降低显著相关(OR 0.364,95%CI 0.142-0.814;p=0.022)。

要点

  • 靶向活检GG≥2患者中,根治标本降级178例(17%),总体过度治疗风险2.7%(28/1020)。
  • 经会阴活检路径与降级风险降低显著相关(OR 0.364,95%CI 0.142-0.814;p=0.022)。
  • 靶向活检GG 2者仅3.2%(18/555)降为GG 1,GG≥3者仅0.6%(3/465)降为GG 1。

核心结论

  • 多中心研究未发现强证据表明靶向活检结果会导致高风险的过度治疗。

研究设计与样本

  • 回顾性识别前瞻性维护数据库(记录8家转诊中心所有根治性前列腺切除手术)中临床局限型前列腺癌、MRI阳性(PI-RADS评分≥3)且MRI靶向活检检出Gleason分级分组(GG)≥2疾病的活检初治患者。
  • 活检分级定义为检出的最高分级;降级定义为根治标本GG低于MRI靶向活检GG。
  • 过度治疗定义为活检GG≥2者根治标本降为GG 1,或活检GG≥3者根治标本降为低负荷GG 2。
  • 共纳入1020例连续活检初治、MRI靶向活检GG≥2的前列腺癌患者。

主要发现

  • 根治性前列腺切除标本病理分析显示178例(17%)降级。
  • 经会阴活检路径与降级风险降低显著相关(OR 0.364,95%CI 0.142-0.814;p=0.022)。
  • 靶向活检GG 2的555例中,仅18例(3.2%)根治标本降为GG 1。
  • 靶向活检GG≥3的465例中,3例(0.6%)根治标本降为GG 1,7例降为低负荷GG 2。
  • 靶向活检导致的总体过度治疗风险为2.7%(28/1020)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Targeted biopsy of the index prostate cancer (PCa) lesion on multiparametric magnetic resonance imaging (MRI) is effective in reducing the risk of overdiagnosis of indolent PCa. However, it remains to be determined whether MRI-targeted biopsy can lead to a stage shift via overgrading of the index lesion by focusing only on the highest-grade component, and to a subsequent risk of overtreatment. Our aim was to assess whether overgrading on MRI-targeted biopsy may lead to overtreatment, using radical prostatectomy (RP) specimens as the reference standard. METHODS: Patients with clinically localized PCa who had positive MRI findings (Prostate Imaging-Reporting and Data System [PI-RADS] score ≥3) and Gleason grade group (GG) ≥2 disease detected on MRI-targeted biopsy were retrospectively identified from a prospectively maintained database that records all RP procedures from eight referral centers. Biopsy grade was defined as the highest grade detected. Downgrading was defined as lower GG for the RP specimen than for MRI-targeted biopsy. Overtreatment was defined as downgrading to RP GG 1 for cases with GG ≥2 on biopsy, or to RP low-burden GG 2 for cases with GG ≥3 on biopsy. KEY FINDINGS AND LIMITATIONS: We included 1020 consecutive biopsy-naïve patients with GG ≥2 PCa on MRI-targeted biopsy in the study. Pathological analysis of RP specimens showed downgrading in 178 patients (17%). The transperineal biopsy route was significantly associated with a lower risk of downgrading (odds ratio 0.364, 95% confidence interval 0.142-0.814; p = 0.022). Among 555 patients with GG 2 on targeted biopsy, only 18 (3.2%) were downgraded to GG 1 on RP. Among 465 patients with GG ≥3 on targeted biopsy, three (0.6%) were downgraded to GG 1 and seven were downgraded to low-burden GG 2 on RP. The overall risk of overtreatment due to targeted biopsy was 2.7% (28/1020). CONCLUSIONS AND CLINICAL IMPLICATIONS: Our multicenter study revealed no strong evidence that targeted biopsy results could lead to a high risk of overtreatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Baboudjian M, Diamand R, Uleri A, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. 2024. PMID: 38494379. doi:10.1016/j.eururo.2024.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。